#### **PARASYMPATHOMIMETICS** (Directly Acting Cholinomimetics)

66

Dr. Zunera Hakim

99

- Katzung's Basic & Clinical Pharmacology, 16<sup>th</sup> Edition
- Goodman and Gilmans The Pharmacological Basis of Therapeutics, 13<sup>th</sup> Edition



# **MOTO & VISION**



- To impart evidence based research oriented medical education
- To provide best possible patient care
- To inculcate the values of mutual respect and ethical practice of medicine



## **UMAR'S MODEL OF INTEGRATION**







#### **LEARNING OBJECTIVES**



At the end of the lecture, students of 3<sup>rd</sup> Year MBBS will be able to;

- **01** Recall the organization and physiology of parasympathetic system
- **02** Classify cholinomimetics
- **03** Identify location of cholinergic receptors and molecular mechanism of their activation
- 04 Describe the pharmacological effects produced by the activation of these receptors
- **05** Describe uses and adverse effects of cholinomimetics





- 1. Which of the following cholinomimetic has the shortest duration of action?
- A. Carbachol
- B. Bethanechol
- C. Acetylcholine (Ach)
- D. Cevimeline
- E. Methacholine
- 2. How many acetylcholine bind with ligand-gated ion (N+) channel?
- A. One B. Two C. Three D. Four E. Five
- 3. AcH is packaged into vesicles by VAT with efflux of which ions?
- A. Hydrogen
- B. Sodium
- C. Potassium
- D. Calcium
- E. Chloride





- **4**. In the ligand-gated ion channel, Ach binds to:
- A) Alpha subunits
- B) Beta subunits.
- C) Gamma subunits
- D) A&B
- E) A & C

5.Which muscarinic cholinomimetic can be used to diagnose asthma?

- A. Carbachol
- B. Bethanechol
- C. Acetylcholine (Ach)
- D. Cevimeline
- E. Methacholine





6. What is the primary reason for the limited therapeutic usefulness of Acetylcholine (ACh)?

- A. Rapid degradation by cholinesterases
- **B. Slow degradation by cholinesterases**
- C. Low affinity for all types of cholinoceptors
- D. High selectivity for all types of cholinoceptors
- **E.** Selectivity for nicotinic receptors
- 7. Which of the following direct-acting cholinomimetics is mainly muscarinic in action?
- A. Bethanechol
- B. Carbachol
- C. Acetylcholine
- D. Atropine
- E. Pilocarpine





8.A 65 year-old retired woman reports to ER after becoming suddenly ill following her evening meal. Her presenting features include marked perspiration, excessive tear formation, nausea, drooling, pinpoint pupils & bradycardia. When asked about her recent history, she mentions having made a salad for dinner containing store bought lettuce, tomatoes, vinegar & oil dressing, and some wild mushrooms that she hand-picked from the overgrown section of City Park .Assuming she is suffering from food poisoning, what active ingredient would best explain her signs & symptoms?

- A. Atropine
- B. Muscarine
- C. Scopolamine
- D. Hysocine
- E. Cocaine





9. A 43 year-old patient is recovering from abdominal surgery and develops postoperative urinary retention. A drug that you could give orally to treat this condition is:

- A. Bethanechol
- B. Atropine
- C. Acetycholine
- D. Pilocarpine
- E. Clonidine

10. Which one of the following drugs are used to treat dry mouth symptom that associated with Sjogren's syndrome?

- A. Carbachol
- B. Bethanechol
- C. Acetylcholine (Ach)
- D. Cevimeline
- E. Methacholine



#### SPIRAL INTEGRATION WITH PHYSIOLOGY



# Parasympathetic Neurotransmission







### **Parasympathetic Neurotransmission**



**Termination of effect of released Ach Released AcH is metabolized by 1. Acetycholinesterase** cholinergic neuroeffector junction and NMJ 2. Butyrylcholineterase (Pseudocholinesterase) liver and plasma

SPIRAL INTEGRATION WITH PHYSIOLOGY

#### PARASYMPATHOMIMETICS/CH OLINOMIMETICS

Drugs that mimic the actions of the parasympathetic nervous system stimulation on target organs are called parasympathomimetics, or cholinomimetics

### **CLASSIFICATION OF PARASYMPATHOMIMETICS**



### CLASSIFICATION OF PARASYMPATHOMIMETICS

#### **A. Directly Acting Cholinomimetics**

Drugs acting on cholinoceptors

#### **B. Indirectly Acting Cholinomimetics**

Drugs inhibiting acetylcholinesterase and increasing the concentration of endogeneously released acetycholine augmenting acetycholine signal transduction

#### CLASSIFICATION (Directly Acting)

#### **I. Choline Ester**

Acetyl choline Carbachol Methacholine Bethanechol

#### **II. Cholinomimetic Alkaloids**

- a. Mainly Muscarinic Agonists Natural Alkaloids: Muscarine Pilocarpine Arecholine
  Synthetic Alkaloid: Oxotremorine, Cevimiline
- b. Mainly Nicotinic Agonists Natural Alkaloids: Nicotine Lobeline
  Synthetic Alkaloids: Dimethylphenylpiperazinium(DMPP) Vareniciline

### **CHOLINOCEPTORS**



**CORE-PHARMACOLOGY** 



# **CHOLINOCEPTORS**

#### Table 13.2 Muscarinic receptor subtypes\*

	M₁ ('neural')	M <sub>2</sub> ('cardiac')	M <sub>3</sub> ('glandular/ smooth muscle')	M4	M <sub>5</sub>
Main locations	Autonomic ganglia (including intramural ganglia in stomach) Glands: salivary, lacrimal, etc. Cerebral cortex	Heart: atria CNS: widely distributed	Exocrine glands: gastric (acid-secreting parietal cells), salivary, etc. Smooth muscle: gastrointestinal tract, eye, airways, bladder Blood vessels: endothelium	CNS	CNS: very localised expression in substantia nigra Salivary glands Iris/ciliary muscle
Cellular response	↑ IP <sub>a</sub> , DAG Depolarisation Excitation (slow epsp) ↓ K <sup>+</sup> conductance	↓ cAMP Inhibition ↓ Ca <sup>2+</sup> conductance ↑ K <sup>+</sup> conductance	↑ IP <sub>3</sub> Stimulation ↑ [Ca <sup>24</sup> ],	↓ cAMP Inhibition	↑ IP <sub>3</sub> Excitation
Functional response	CNS excitation (? improved cognition) Gastric secretion	Cardiac inhibition Neural inhibition Central muscarinic effects (e.g. tremor, hypothermia)	Gastric, salivary secretion Gastrointestinal smooth muscle contraction Ocular accommodation Vasodilatation	Enhanced locomotion	Not known

**CORE-PHARMACOLOGY** 

# **CHOLINOCEPTORS**

	Muscle type	Ganglion type	CNS type	es	Notes
Main molecular form	$(\alpha 1)_2\beta 1\delta\epsilon$ (adult form)	(α3) <sub>2</sub> (β2) <sub>3</sub>	(α.4) <sub>2</sub> (β2) <sub>3</sub>	(α7) <sub>5</sub>	
Main synaptic location	Skeletal neuromuscular junction: mainly postsynaptic	Autonomic ganglia: mainly postsynaptic	Many brain regions: pre- and postsynaptic	Many brain regions: pre- and postsynaptic	-
Membrane response	Excitatory Increased cation permeability (mainly Na <sup>+</sup> , K <sup>+</sup> )	Excitatory Increased cation permeability (mainly Na <sup>+</sup> , K <sup>+</sup> )	Pre- and postsynaptic excitation Increased cation permeability (mainly Na <sup>+</sup> , K <sup>+</sup> )	Pre- and postsynaptic excitation Increased cation permeability	(α7)₅ receptor produces large Ca <sup>2+</sup> entry, evoking transmitter release

### **STRUCTURE ACTIVITY RELATIONSHIP**



### **STRUCTURE ACTIVITY RELATIONSHIP**



**CORE-PHARMACOLOGY** 

# **RECEPTOR SELECTIVITY**

		Receptor specificity			
Compound	Structure	<b>M</b> uscarinic	Nicotinic	cholinesterase	
Acetylcholine	0 H <sub>3</sub> C H <sub>3</sub> C CH <sub>3</sub> H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	+++	***	+++	
Carbachol	H <sub>2</sub> N O CH <sub>3</sub> I ⊕ CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	++	+++	-	
Methacholine	0 CH <sub>3</sub> CH <sub>3</sub> H <sub>3</sub> C 0 H <sub>3</sub> CH <sub>3</sub> N=CH <sub>3</sub> CH <sub>3</sub>	+++	+	++	
Bethanechol	0 CH <sub>3</sub> CH <sub>3</sub> I⊕ H₂N 0 I CH <sub>3</sub>	+++		<del></del>	
Muscarine		+++	-11	-	
Pilocarpine		++	-	-	
Oxotremorine		++	-	-	
Cevimeline		++°	-	-	

**CORE-PHARMACOLOGY** 

# **EFFECTS OF ACETYLCHOLINE**

#### Muscarinic action of acetylcholine

Effects of AcH on visceral effectors innervated by parasympathetic system (smooth muscles, heart and exocrine glands)

 <u>Nicotinic action of acetycholine</u> Effects of AcH on autonomic ganglia and adrenal medulla





#### **CENTRAL NERVOUS SYSTEM**

- M1 mAChR mediate cognition-enhancing effects of AcH (cerebral cortex and hippocampus)
- M2 and M4 mAChR mediate muscarinic antinociception at the spinal and the supraspinal level
- M3 mACHR stimulate release of insulin and increase energy expenditure (body fat mass)
- Nicotinic receptors mainly in spinal cord, brainstem & cortex
- Regulate release of neurotransmitters

BRAIN

- Effects range from mild altering action to fatal convulsions
- Mediate cognition and pain perception



#### **CORE-PHARMACOLOGY**



**EYE** 

- Constriction of the pupillary constrictor (M3) resulting in miosis
- Contraction of ciliary muscle (M3)

accommodating the eye for near vision

- Increasing the drainage of aqueous humor
- Increase secretion of lacrimal gland (M3)





#### **RESPIRATORY SYSTEM**

- Contraction of bronchial smooth muscle
  - leading to bronchoconstriction (M3)
- Stimulation of glands in the
  - tracheobronchial tree

BRAIN

Organ system



#### **CARDIOVASCULAR SYSTEM**

#### M3 receptors are present both on the endothelial cells & vascular smooth muscle

• Response depends upon

BRAIN

- Dose of the agonist
- Presence/absence of endothelium
- Low dose (3x10<sup>-7</sup>M) results in NO/cGMP mediated vasodilation
- High dose (10<sup>-7</sup>M) causes vasoconstriction via M3 mediated increase in Ca+





ACh

#### **CARDIOVASCULAR SYSTEM**

#### (HEART)

 Indirect tachycardia due to compensatory sympathetic stimulation in response to low dose vasodilation

BRAIN

- High concentration directly activates M2 receptors in SA and AV node resulting in bradycardia and slowing of AV conduction (increase K+ permeability, decrease in inward Ca+ current)
- Decrease contraction of the atria (hyperpolarization and decrease in cAMP)



#### **GASTROINTESTINAL TRACT**

- Contraction of gastrointestinal smooth muscle (M3) increasing gastrointestinal motility (increase Ca+ influx)
- Stimulate salivary, gastric, and other secretions in the gastrointestinal tract (salivary & gastric > pancreatic & small intestine)
- Relaxation of sphincters (M3)

BRAIN

#### **GENITOURINARY TRACT**

- Contraction of detrusor muscle (M3)
- Relaxation of sphincter (M3) leading to

voiding of urine

BRAIN

Organ system

- M2 cause bladder contraction by reversing
  - $\boldsymbol{\beta}$  receptor cAMP mediated relaxation of

detrusor muscle

• Contraction of pregnant uterus (M3)



#### **SECRETORY GLANDS**



M3 mediated increase in secretion of

- Lacrimal gland
- Salivary gland
- Nasopharyngeal gland
- Sweat gland
- Tracheobronchial glands
- Gastrointestinal glands

# PHARMACOKINETICS

- Acetylcholine & other Choline esters with a permanently charged quaternary ammonium group are poorly absorbed & distributed to the CNS (hydrophilic)
- All are **hydrolysed in the GIT**, rate of hydrolysis differs depending on their susceptibility for the enzyme.
- Carbamic acid esters carbachol and bethanechol have longer duration of action.
- The tertiary cholinomimetic alkaloids (pilocarpine, nicotine, lobeline) are well absorbed from most sites of administration
- Muscarine, a quaternary amine is less completely absorbed from the GIT and is toxic too when mushroom containing this is ingested
- **Excretion** mainly by the kidneys



### **THERAPEUTIC USES**

Drug	<b>Receptor Specificity</b>	Hydrolyzed by Cholinesterase	Route of Administration	Clinical Use
Choline Esters				
Acetylcholine	Muscarinic and nicotinic	Yes	Intraocular Intracoronary	Miosis during ophthalmic surgery Coronary angiography
Bethanechol	Muscarinic	No	Oral or subcutaneous	Gastrointestinal and urinary stimulation
Carbachol	Muscarinic and nicotinic	No	Topical ocular Intraocular	Glaucoma Miosis durina ophthalmic surgery
Plant Alkaloids				3-1
Muscarine	Muscarinic	No	None	None
Nicotine	Nicotinic	No	Oral or transdermal	Smoking cessation programs
Pilocarpine	Muscarinic	No	Topical ocular Oral	Glaucoma Xerostomia
Other Drugs				
Cevimeline	Muscarinic	No	Oral	Xerostomia
Varenicline	Nicotinic	No	Oral	Smoking cessation

### **ADVERSE EFFECTS**

#### **MUSCARINIC EXCESS**

Nausea, vomiting, diarrhea, urinary urgency, salivation, sweating, cutaneous vasodilatation, bronchoconstriction, bradycardia, hypotension and shock

"All faucets turned on syndrome"

#### **NICOTINIC EXCESS**

#### • <u>Acute</u>

- i. CNS stimulation, cause convulsions, coma and respiratory arrest.
- ii. Skeletal muscle depolarization and respiratory paralysis.
- iii. Hypertension and cardiac arrhythmia

#### <u>Chronic</u>

i.

- Increased risk of vascular disease
- ii. Sudden coronary death
- iii. Aggravation of peptic ulcer in smokers

# CONTRAINDICATIONS

- Bronchial asthma
- GI or urinary tract obstruction
- Peptic ulcer
- Recent myocardial infarction
- Coronary insufficiency
- Hyperthyroidism

### RESEARCH



Johnson, Chad R., Brian D. Kangas, Emily M. Jutkiewicz, Jack Bergman, and Andrew Coop. 2022. "Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders" *Biomedicines* 10, no. 2: 398. https://doi.org/10.3390/biomedicines10020398

### **BIOETHICS**



Hammond D, Reid JL, Rynard VL, *et al* Indicators of dependence and efforts to quit vaping and smoking among youth in Canada, England and the USA *Tobacco Control* 2022;**31:**e25-e34.

# **ARTIFICIAL INTELLIGENCE**



Researchers use computer simulations to study how neuroreceptors respond to nicotine

Oliveira, A.S.F., *et al.* (2019) A General Mechanism for Signal Propagation in the Nicotinic Acetylcholine Receptor Family. *Journal of the American Chemical Society*. doi.org/10.1021/jacs.9b09055.

Researchers are now working with Achieve Life Sciences to design and develop molecules that mimic nicotine, and computer simulations that will help test their potential effectiveness. This work builds on previous studies using chemical synthetic approaches to develop new smoking cessation aids, which will be investigated and tested in simulation scenarios.